Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

This approach offers an enhanced therapeutic effect with minimal systemic toxicity, addressing one of oncology’s ...

In line with its deregulatory stance under new Commissioner Marty Makary, the US regulator has launched TEMPO – ...

Social determinants of health (SDOH) encompass a wide range of non-medical factors that influence health and well-being.

And Simon Kohl, founder and CEO of Latent Labs, knows this intimately. In a new episode of the pharmaphorum podcast, Kohl ...